Sakai Hitomi

Researcher

基本情報

Profile and Settings

• 氏名

  Sakai Hitomi

• eメール

  sakai-hmed.showa-u.ac.jp

Affiliation

• Advanced Cancer Translational Research Institute, Associate Professor

Location

• Hatanodai Campus

Degree

• Doctor of Medical Science, Kindai University, Mar. 2020

Association Memberships

• American Society of Clinical Oncology
• European Society of Medical Oncolog
• Multinational Association for Supportive Care in Cancer

Committee Memberships

• Japanese Breast Cancer Society, Clinical Practice Guidelines Committee, Drug Therapy Subcommittee, Oct. 2022
• Japanese Society of Supportive Care in Cancer, Guideline Development Committee for Appearance Care Guidelines in Cancer Treatment, 2021 Edition
• Western Japan Oncology Group (WJOG), Breast Cancer Young Researchers Group BRIGHT, Representative, Apr. 2022, Mar. 2024
• Western Japan Oncology Group (WJOG), Breast Cancer Young Researchers Group BRIGHT, Steering Committee, Feb. 2019

Awards

• Japanese Society of Clinical Oncology, Encouragement Award, 2019
• Western Japan Oncology Group (WJOG) Toranohora MVP, Aug. 2017

Academic Contributions

• JSMO, Competition etc, Others, Seminar on Medical Oncology for Students and Residents / Randomized Controled Study on Antiemetic Therapy for Trastuzumab Deruxtecan (ERICA, WJOG14320B), 18 Mar. 2023
• Academic society etc, Others, Global Breast Cancer Conference 2023, Junior Doctors Forum & Debate, 29 Apr. 2023, Seoul

Social Contributions

• Lecture, Lecturer, Osaka Oncology Seminar Meeting the Cancer Experts 'Night School' 2023, 13 Oct. 2023, https://www.youtube.com/watch?v=4ybYMvZt8Vw

Achievements

Published Papers

• Risk factors for recurrence in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer in Japan: a systematic literature review and meta-analysis, Miyazaki N, Iwasaki T, Sakai H, et al., Curr Med Res Opin., Apr. 2024, Peer-reviewed, DOI:10.1080/03007995.2024.2332436
• 抗体薬物複合体に対する耐性と克服(T-DM1とT-DXdなど), 鶴谷 純司;酒井 瞳, 腫瘍内科, 32(5):575, Nov. 2023
• The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition., Terada Mitsuo;Ito Aki;Kikawa Yuichiro;Koizumi Kei;Naito Yoichi;Shimoi Tatsunori;Ishihara Mikiya;Yamanaka Takashi;Ozaki Yukinori;Hara Fumikata;Nakamura Rikiya;Hattori Masaya;Miyashita Minoru;Kondo Naoto;Yoshinami Tetsuhiro;Takada Masahiro;Matsumoto Koji;Narui Kazukata;Sasada Shinsuke;Iwamoto Takayuki;Hosoda Mitsuchika;Takano Yuko;Oba Takaaki;Sakai Hitomi;Murakami Akari;Higuchi Toru;Tsuchida Junko;Tanabe Yuko;Shigechi Tomoko;Tokuda Emi;Harao Michiko;Kashiwagi Shinichiro;Mase Junichi;Watanabe Junichiro;Nagai Shigenori E;Yamauchi Chikako;Yamamoto Yutaka;Iwata Hiroji;Saji Shigehira;Toyama Tatsuya, Breast cancer (Tokyo, Japan), 30(6), Oct. 2023, Peer-reviewed
• Protocol for a Prospective Cohort Study to Evaluate Changes in Sexuality in Patients With Primary Cervical Cancer Using Patient-Reported Outcomes (JGOG9004, SARAH Study), and Our Approaches to Solving the Unmet Needs of Patients With Gynecological Cancer, Hitomi Sakai, et al., Journal of Clinical Gynecology & Obstetrics, 12(2):59 - 64, Aug. 2023, Peer-reviewed, DOI:https://doi.org/10.14740/jcgo892
• Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B)., Masuda Hiroko;Tanabe Yuko;Sakai Hitomi;Matsumoto Koji;Shimomura Akihiko;Doi Mihoko;Miyoshi Yasuo;Takahashi Masato;Sagara Yasuaki;Tokunaga Shinya;Iwasa Tsutomu;Niikura Naoki;Yoshimura Kenichi;Takano Toshimi;Tsurutani Junji, Breast (Edinburgh, Scotland), 71, Jul. 2023, Peer-reviewed
• Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B), Hitomi Sakai; Junji Tsurutani; Yukinori Ozaki; Hiroshi Ishiguro; Kazuki Nozawa; Kenichi Watanabe; Shigeto Maeda; Takamichi Yokoe; Chiyo K Imamura; Koji Matsumoto; Tsutomu Iwasa; Yasutaka Chiba; Daisuke Takiguchi; Toshimi Takano, BMJ Open, 13(4):e070304 - e070304, Apr. 2023, Peer-reviewed
• Comparison of older and younger patients with ovarian cancer: A post hoc study (JGOG3016-A3) of the treatment strength and prognostic outcomes of conventional or dose-dense chemotherapy., Itani Yoshio;Sakai Hitomi;Hamano Tetsutaro;Asai-Sato Mikiko;Futagami Masayuki;Fujimura Masaki;Aoki Yoichi;Suzuki Nao;Yoshida Yoshio;Enomoto Takayuki, The journal of obstetrics and gynaecology research, 49(5), Mar. 2023, Peer-reviewed
• 【周術期薬物療法up to date】HER2陽性乳癌の周術期薬物療法, 酒井 瞳, 乳癌の臨床, 38(1):17, Feb. 2023
• Perceptions and practice patterns of cancer survivorship care among Japanese gynecologic oncologists: The JGOG questionnaire survey., Mikiko Asai-Sato; Nao Suzuki; Hitomi Sakai; Yoshio Itani; Shinya Sato; Masayuki Futagami; Yoshio Yoshida, Journal of gynecologic oncology, 34(1):e10, Jan. 2023, Peer-reviewed
• Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)., Masuda Jun;Sakai Hitomi;Tsurutani Junji;Tanabe Yuko;Masuda Norikazu;Iwasa Tsutomu;Takahashi Masato;Futamura Manabu;Matsumoto Koji;Aogi Kenjiro;Iwata Hiroji;Hosonaga Mari;Mukohara Toru;Yoshimura Kiyoshi;Imamura Chiyo K;Miura Sakiko;Yamochi Toshiko;Kawabata Hidetaka;Yasojima Hiroyuki;Tomioka Nobumoto;Yoshimura Kenichi;Takano Toshimi, Journal for immunotherapy of cancer, 11(9), 2023, Peer-reviewed
• 【乳がん診療の進歩と展望】乳がんにおける抗体薬物複合体(ADC)の展望, 酒井 瞳, 腫瘍内科, 30(2):132, Aug. 2022
• 【女性のがん～治療とケアの最前線～】治療の最前線　転移再発乳がんの最新治療　薬物療法, 酒井 瞳, がん看護, 27(6):565, Jul. 2022
• 【HBOC診療の現状と今後の展開】HBOCにおける新規薬物療法:PARP阻害薬, 酒井 瞳, 乳癌の臨床, 37(1):33, Mar. 2022
• 【図解　分子メカニズムから理解する婦人科がんの薬物療法】総論　抗悪性腫瘍薬使用時の副作用に対する対策　下痢と便秘, 酒井 瞳, 産婦人科の実際, 70(12):1356, Nov. 2021
• KRAS inhibitor-resistance in MET-amplified KRAS G12C non-small cell lung cancer induced by RAS- and non-RAS-mediated cell signaling mechanisms., Shinichiro Suzuki; Kimio Yonesaka; Takeshi Teramura; Toshiyuki Takehara; Ryoji Kato; Hitomi Sakai; Koji Haratani; Junko Tanizaki; Hisato Kawakami; Hidetoshi Hayashi; Kazuko Sakai; Kazuto Nishio; Kazuhiko Nakagawa, Clinical cancer research : an official journal of the American Association for Cancer Research, 27(20):5697 - 5707, Aug. 2021, Peer-reviewed
• Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer., Hitomi Sakai; Hisato Kawakami; Takeshi Teramura; Yuta Onodera; Elizabeth Somers; Keiji Furuuchi; Toshimitsu Uenaka; Ryoji Kato; Kazuhiko Nakagawa, Clinical and translational medicine, 11(6):e454, Jun. 2021, Peer-reviewed
• Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts., Ryoji Kato; Koji Haratani; Hidetoshi Hayashi; Kazuko Sakai; Hitomi Sakai; Hisato Kawakami; Kaoru Tanaka; Masayuki Takeda; Kimio Yonesaka; Kazuto Nishio; Kazuhiko Nakagawa, British journal of cancer, 124(5):914 - 924, Mar. 2021, Peer-reviewed
• Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B)., Takamichi Yokoe; Sasagu Kurozumi; Kazuki Nozawa; Yukinori Ozaki; Tetsuyo Maeda; Shu Yazaki; Mai Onishi; Akihiro Fujimoto; Sayuka Nakayama; Yuko Tsuboguchi; Tsutomu Iwasa; Hitomi Sakai; Misato Ogata; Mitsuo Terada; Meiko Nishimura; Takuma Onoe; Jun Masuda; Michiko Kurikawa; Hirotsugu Isaka; Kanako Hagio; Akihiko Shimomura; Yuta Okumura; Manabu Futamura; Mototsugu Shimokawa; Toshimi Takano, Breast cancer (Tokyo, Japan), 28(3):581 - 591, Jan. 2021, Peer-reviewed
• Psychosocial effects of appearance changes due to cancer treatment and needs for information and supportive care in Japanese cancer patients., Hitomi Sakai; Atsuko Koyama; Kaoru Tanaka; Satomi Watanabe; Miki Nakura; Toshiko Yasuda; Makiko Hayashi; Miyuki Endo; Kazuhiko Nakagawa, Asia-Pacific journal of clinical oncology, 16(5):e185-e191, Oct. 2020, Peer-reviewed
• Long-term response to ipilimumab after nivolumab failure in a case of anorectal melanoma with an intermediate tumor mutation burden and negative for PD-L1 expression., Hitomi Sakai; Masayuki Takeda; Kazuko Sakai; Kazuto Nishio; Kazuhiko Nakagawa, Molecular and clinical oncology, 13(2):175 - 178, Aug. 2020, Peer-reviewed
• How do doctors choose treatment for older gynecological cancer patients? A Japanese Gynecologic Oncology Group survey of gynecologic oncologists., Makoto Yamamoto; Yoshio Yoshida; Yoshio Itani; Shinya Sato; Masayuki Futagami; Hitomi Sakai; Hiroaki Kajiyama; Masaki Fujimura; Yoichi Aoki, International journal of clinical oncology, 25(4):741 - 745, Apr. 2020, Peer-reviewed
• Percutaneous transthoracic needle biopsy of the lung in the era of precision medicine., Hitomi Sakai; Masayuki Takeda, Journal of thoracic disease, 11(Suppl 9):S1213-S1215, May 2019
• Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion., Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K, Lung cancer (Amsterdam, Netherlands), 127:59 - 65, Jan. 2019, Peer-reviewed
• HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine(T-DM1) in patients with HER2-positive metastatic breast cancer, Sakai Hitomi; Tsurutani Junji; Iwasa Tsutomu; Komoike Yoshifumi; Sakai Kazuko; Nishio Kazuto; Nakagawa Kazuhiko, Breast Cancer, 25(5):605 - 613, Sep. 2018, Peer-reviewed
• B7-H3 negatively modulates CTL-mediated cancer immunity., Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K, Clinical cancer research : an official journal of the American Association for Cancer Research, 24(11):2653 - 2664, Mar. 2018, Peer-reviewed
• 【乳がんに対する新しい診断法や治療法】ホルモン受容体陽性進行乳がんに対するCDK4/6阻害薬, 酒井 瞳; 鶴谷 純司, 腫瘍内科, 20(3):194 - 198, Sep. 2017
• Providing written information increases patient satisfaction: a web-based questionnaire survey of Japanese cancer survivors, Hitomi Sakai; Noriyuki Katsumata; Miyako Takahashi, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 47(7):611 - 617, Jul. 2017, Peer-reviewed
• 多遺伝子アッセイを用いた乳がん化学療法省略の可能性 TAILORx試験およびMINDACT試験の結果から, 酒井 瞳; 鶴谷 純司, がん分子標的治療, 14(4):511 - 513, Jan. 2017
• Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR., Sakai H; Hayashi H; Iwasa T; Hasegawa Y; Takeda M; Nakagawa K, ESMO open, 2(Suppl 1):e000104, 2017, Peer-reviewed
• [Acute Hyperuricemia and Kidney Injury after Three Cycles of Dose-Dense Chemotherapy for Retroperitoneal Choriocarcinoma -- A Case Report]., Sakai H; Matsuda M; Kadokura G; Katsumata N, Gan to kagaku ryoho. Cancer & chemotherapy, 43(2):263 - 266, Feb. 2016, Peer-reviewed
• Attitudes and practice patterns for maintaining relative dose intensity of chemotherapy in outpatient clinics: results of a Japanese web-based survey, Hitomi Sakai; Noriyuki Katsumata; Genmu Kadokura, BMC CANCER, 15:651, Oct. 2015, Peer-reviewed
• Recovery of a misinserted gastrostomy tube during replacement: Effectiveness of gastropexy using a 'Funada style' kit, Hitomi Sakai; Masahiko Inamori; Hiroshi Iida; Keiko Akimoto; Hiroki Endo; Yuichi Nozaki; Tomoyuki Akiyama; Yasunari Sakamoto; Koji Fujita; Hirokazu Takahashi; Masato Yoneda; Yasunobu Abe; Kensuke Kubota; Norio Ueno; Akihiko Kusakabe; Atsushi Nakajima, DIGESTION, 75(4):179 - 179, 2007, Peer-reviewed
• Protein-losing gastroenteropathy and gastric polyps: successful treatment by Helicobacter pylori eradication., Sato T; Chiguchi G; Inamori M; Sakai H; Fujisawa N; Akiyama T; Akimoto K; Fujita K; Takahashi H; Yoneda M; Abe Y; Kubota K; Ueno N; Nakajima A, Digestion, 75:99, 2007, Peer-reviewed

Presentations

• Roles of Probiotics, Trimebutine Maleate, and Loperamide in Abemaciclib-Induced Diarrhea (WJOG11318B, MERMAID), Hitomi Sakai, et al., JSMO2024, 23 Feb. 2024
• Toxicity of combination therapy with nivolumab and abemaciclib in HR-positive metastatic breast cancer: WJOG11418B, Hitomi Sakai, et al., JSMO2024, 22 Feb. 2024
• WJOG (West Japan Oncology Group) Breast Cancer Consensus Meeting 2023, Yuri Kimura, Hitomi Sakai, et al., JSMO2024, 22 Feb. 2024
• A randomized, double-blind, placebo-controlled study of olanzapine for CINV during T-DXd in HER2 positive metastatic breast cancer patients: WJOG14320B (ERICA), Hitomi Sakai, Junji Tsurutani, Takamichi Yokoe, Chiyo K Imamura, Koji Matsumoto, Tsutomu Iwasa, Yasutaka Chiba, Yuji Hirakawa and Toshimi Takano, GBCC, 27 Apr. 2023
• P65-5 西日本がん研究機構（WJOG)の若手ブレストオンコロジストを対象にした4か月間の臨床試験教育プログラムの報告, Hitomi Sakai, et al., JSMO2023, 18 Mar. 2023
• SY09-2 生殖細胞系列BRCA1/2変異陽性乳癌の術後オラパリブ治療, Hitomi Sakai, JSMO2023, 16 Mar. 2023
• HER2+ mBC患者を対象としたT-DXd投与中のCINVに対するオランザピン投与の第II相試験　WJOG14320B(ERICA)(Phase II study of olanzapine for CINV during T-DXd in HER2+ mBC patients: WJOG14320B(ERICA)), 酒井 瞳;鶴谷 純司;横江 隆道;今村 知世;松本 光史;岩朝 勤;千葉 康敬;平川 雄士;高野 利実, 日本乳癌学会総会プログラム抄録集, Jun. 2022
• MET-amplifiedによるKRASG12C阻害薬の獲得耐性とメカニズム, 鈴木 慎一郎; 米阪 仁雄; 寺村 岳士; 竹原 俊幸; 加藤 了資; 酒井 瞳; 原谷 浩司; 谷崎 潤子; 川上 尚人; 林 秀敏; 坂井 和子; 西尾 和人; 中川 和彦, 肺癌, Oct. 2021
• 当院におけるアベマシクリブの使用経験, 黒崎 隆; 岩朝 勤; 渡邉 諭美; 酒井 瞳; 橋本 幸彦; 菰池 佳史; 中川 和彦, 日本乳癌学会総会プログラム抄録集, Oct. 2020
• 転移性HER2陽性乳癌に対するT-DM1後の治療の臨床効果に関する多施設共同コホート研究(WJOG12519B), 西村 明子; 横江 隆道; 黒住 献; 能澤 一樹; 尾崎 由記範; 前田 哲代; 矢崎 秀; 大西 舞; 藤本 章博; 中山 紗由香; 坪口 裕子; 酒井 瞳; 緒方 美里; 寺田 満雄; 尾上 琢磨; 伊坂 泰嗣; 萩尾 加奈子; 下村 昭彦; 下川 元継; 高野 利実, 日本乳癌学会総会プログラム抄録集, Oct. 2020
• 持続する上部消化管出血と高度直腸狭窄を伴うも経口摂取を継続した若年の原発不明癌症例, 酒井 瞳; 川中 雄介; 田中 薫; 武田 真幸; 前田 宗之; 中川 和彦, Palliative Care Research, Aug. 2020
• 実臨床におけるリキッドバイオプシーの役割 CAPP-Seqを用いたLiquid biopsyによるT790M陽性非小細胞肺癌のオシメルチニブ耐性因子の検討, 加藤 了資; 林 秀敏; 米阪 仁雄; 原谷 浩司; 酒井 瞳; 高濱 隆幸; 岩朝 勤; 田中 薫; 吉田 健史; 武田 真幸; 金田 裕靖; 清水 重喜; 坂井 和子; 伊藤 彰彦; 西尾 和人; 中川 和彦, 肺癌, Nov. 2019
• ALK融合遺伝子陽性非小細胞肺癌におけるALK-TKI耐性機序に関する検討, 田中 薫; 谷崎 潤子; 野長瀬 祥兼; 原谷 浩司; 酒井 瞳; 加藤 了資; 渡邉 諭美; 吉田 健史; 佐藤 千尋; 林 秀敏; 坂井 和子; 西尾 和人; 中川 和彦, 肺癌, Nov. 2019
• A questionnaire survey for psychosocial effects of appearance changes due to cancer treatment and needs for information and supportive care in Japanese cancer patients, Hitomi Sakai, Atsuko Koyama, Kaoru Tanaka, Satomi Watanabe, Miki Nakura, Noriko Yasuda, Makiko Hayashi, Miyuki Endo, and Kazuhiko Nakagawa, MASCC, 21 Jun. 2019
• 初発骨転移症例の予後規定因子の検討, 菰池 佳史; 東 千尋; 田中 裕美子; 濱田 未佳; 新崎 亘; 橋本 幸彦; 北條 敏也; 乾 浩己; 鶴谷 純司; 岩朝 勤; 酒井 瞳; 大和 宗久; 金泉 博文; 山村 順, 日本乳癌学会総会プログラム抄録集, May 2018
• 当院における高齢者への化学療法施行の現状に関して, 岩朝 勤; 鶴谷 純司; 酒井 瞳; 渡邊 諭美; 新崎 亘; 安積 達也; 橋本 幸彦; 菰池 佳史, 日本乳癌学会総会プログラム抄録集, May 2018
• 乳癌化学療法による外見変化に対する医師の認識と介入の実態調査, 酒井 瞳; 岩朝 勤; 鶴谷 純司; 菰池 佳史, 日本乳癌学会総会プログラム抄録集, May 2018

Books etc

• 乳癌薬物療法の要点と盲点, 佐治重衡, 増田慎三, 酒井瞳他, Contributor, 文光堂, Jun. 2023
• 誰も教えてくれなかった婦人科がん薬物療法, 勝俣範之, 酒井瞳, et al., MEDICAL VIEW, May 2020
• 実践がんサバイバ-シップ: 患者の人生を共に考えるがん医療をめざして, 山内 英子 , 松岡 順治, 酒井 瞳, et al., Contributor, 医学書院, Apr. 2014

Research Projects

• Research on cerebrospinal fluid ctDNA testing for the development of treatment for HER2-negative breast cancer brain metastasis and leptomeningeal carcinomatosis, Hitomi Sakai, Principal investigator, Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research, 若手研究, From 20220401, Competitive research funding
• 子宮頸がん患者 の治療後の性機能障害と不安・抑うつの患者報告アウト カムを用いた 前向き コホート研究子宮頸がん患者 の治療後の性機能障害と不安・抑うつの患者報告アウト カムを用いた 前向き コホート研究, Hitomi Sakai, Japan Cancer Society, 2021年度リレー・フォー・ライフ・ジャパン（ＲＦＬＪ） 「プロジェクト未来」, From 20210401